NCT02442414 - A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2015

Primary Completion Date

November 26, 2019

Study Completion Date

November 26, 2019

Conditions

Advanced Solid Tumors

Interventions

DRUG

KBP-5209

Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.

Trial Locations (3)

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

University of Texas MD Anderson Cancer Center, Houston

University of Utah Huntsman Cancer Institute, Salt Lake City